摘要
目的观察孟鲁司特联合丙酸氟替卡松防治儿童哮喘的临床疗效。方法 80例哮喘患儿,随机分为观察组40例和对照组40例。对照组在常规治疗基础上,给予丙酸氟替卡松吸入气雾剂,200~800μg/d,根据病情程度选择不同剂量,连续服用30 d;观察组在对照组的基础上口服孟鲁司特,4~5 mg/次,1次/d,睡前服用,连续服用30 d。比较2组治疗后2、4周哮喘缓解例数;临床症状缓解时间、肺部体征消失时间;采用呼气峰流速(PEF)仪检测PEF。所有患儿随访6个月,统计随访期间复发情况。采用SPSS17.0统计软件,计数资料采用χ2分析,计量资料采用t检验。结果观察组治疗2、4周哮喘缓解例数(15、31例)均高于对照组(7、20例);临床症状缓解时间(2.92±0.62)d、肺部体征消失时间(4.67±0.68)d,均短于对照组(4.69±0.73)d、(5.98±0.56)d,差异有统计学意义(P<0.05或P<0.01);2组治疗后2周、4周PEF均较治疗前升高,观察组较对照组升高更明显,差异有统计学意义(P均<0.05);观察组随访6个月的复发率(2.5%)低于对照组(22.5%)(P<0.01)。结论孟鲁司特联合丙酸氟替卡松防治儿童哮喘的临床疗效确切。
Objective To evaluate the combined usage of montelukast and fluticasone propionate in the treatment and prevention of childhood asthma. Methods A total of 80 cases with childhood asthma that met the selection criteria were randomly divided into two groups(control and observation) of equal size.Patients in the control group were administered with fluticasone propionate for 30 d using the dosage of200-800 mg/d according to the disease severity. Patients in the observation group were administered with fluticasone propionate similar to the control group except that additional montelukast was administered with the dosage of 4-5 mg/d for 30 d once before bedtime. The number of cases with asthma remission was measured 2 and 4 weeks post-treatment. The time of clinical symptoms improvement and pulmonary symptoms disappearance were recorded and the peak expiratory flow(PEF) were detected using a PFE meter. All patients were followed up for 6 months after treatment and the indices of recurrence were analyzed. Results The number of cases with asthma remission 2- and 4-week after the initiation of treatment in the observation group were 15 and 31, respectively, while those in the control group were 7 and 20, respectively. The differences between the control and observation groups were statistically significant(P<0.05). The time of symptoms improvement and the time of disappearance of pulmonary signs were(2.92±0.62)d and(4.67±0.68)d, respectively, which were significantly shorter than those of control group(4.69±0.73)d and(5.98±0.56)d, with P<0.05 and P<0.01, respectively.PEF of the observation group and control group 2- and 4-week after the initiation of treatment were significantly higher than before treatment(all P<0.05). PEF of observation group of 2- and 4-week were significantly higher than the control group(all P <0.05). The recurrence rate of the observation group during the 6 months follow-up period were significantly lower than control group(P<0.05). Conclusions The combined usage of montelukast and fluticasone propionate can more effectively improve symptoms and signs, improve lung function, and reduce disease recurrence than using fluticasone propionate alone, thereby representing a better treatment of childood asthma.
出处
《慢性病学杂志》
2014年第7期543-545,共3页
Chronic Pathematology Journal
